Anzeige
Mehr »
Login
Freitag, 17.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
409 Leser
Artikel bewerten:
(2)

Europe IV Hydration Therapy Market to Surpass US$ 427.0 Million by 2030 - Coherent Market Insights

Finanznachrichten News

SEATTLE, May 30, 2022 /PRNewswire/ -- According to Coherent Market Insights, the Europe IV Hydration Therapy Market is estimated to be valued at US$ 244.1 million in 2022 and is expected to exhibit a CAGR of 7.2% during the forecast period (2022-2030).

Coherent Market Insights Logo

Key Trends and Analysis of the Europe IV Hydration Therapy Market:

The increasing establishments of clinics offering IV hydration treatments is expected to drive the market growth over the forecast period. For instance, in 2018, Cryojuvenate UK Ltd., a cryotherapy clinic, launched a Reviv IV fusions and vitamin booster clinic for REVIV treatments, providing intravenous (IV) shots for various diseases and conditions such as cardiovascular health, nutrient deficiency, vitamin deficiency, and aging signs.

Request Sample Copy of this Report at https://www.coherentmarketinsights.com/insight/request-sample/5021

Key Market Takeaways:

The Europe IV hydration therapy market is expected to exhibit a CAGR of 7.2% during the forecast period due to the increasing prevalence of infections. For instance, according to the data published by the European Food Safety Authority in December 2019, it was estimated that around 91,857 cases of Salmonellosis and 246,571 cases of Campylobacteriosis were reported in the European Union (EU) in 2018, thus making Campylobacteriosis the most commonly reported gastrointestinal infection.

Among component type, the medicated segment is expected to dominate the segment growth over the forecast period, as market players are involved in offering a variety of customizable medicated IV hydration therapies to meet the customer's requirement, which is expected to be a major driving factor for the growth of this segment. For instance, Drip Hydration, a mobile IV Therapy company serving all over Europe, offers Stomach Flu IV treatment, which involves infusion of a blend of fluids, vitamins, electrolytes, and medications to cure symptoms of stomach flu and restore hydration in the body within 30 - 60 minutes. The ingredients of this IV therapy include B-Complex Vitamins, Vitamin B12, Vitamin C, Pepcid, and Zofran. Moreover, Zofran is an anti-nausea/vomiting medicine that helps to relieve nausea and vomiting, which may be caused due to stomach flu.

On the basis of country, Germany is estimated to account for largest share in the Europe IV hydration therapy market over the forecast period. This is mainly attributed to the increasing prevalence of cancer and rising demand for IV hydration therapy for treatment. For instance, the data published by Robert Koch Institute, a German federal government agency and research institute responsible for disease control and prevention, in March 2021, stated that 489,178 people in Germany were diagnosed with cancer, among those 230,150 were women and 259,028 were men in 2017.

Key players operating in the Europe IV hydration therapy market include REVITA, Ivtherapygreece, IV Boost UK, Harpal Clinic Limited, IV Drips London, VITAMIN INJECTIONS LONDON, Cryojuvenate UK Ltd., Italy Health Retreats, Séchoir, ELIXIR, Swiss Medical Centre, Drip Hydration, REVIV, VITANOVAS, and The IV Doc Inc.

Request for Customization at https://www.coherentmarketinsights.com/insight/request-customization/5021

Detailed Segmentation:

Europe IV Hydration Therapy Market, By Service Type:

    • Immune Booster
    • Hangover Cure
    • Energy Booster
    • Skin Care
    • Others

Europe IV Hydration Therapy Market, By Component Type:

    • Medicated
    • Non-Medicated

Europe IV Hydration Therapy Market, By Activity:

    • Emergency Healthcare
    • Routine Healthcare

Europe IV Hydration Therapy Market, By Country:

    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Austria
    • Switzerland
    • The Netherlands
    • Belgium
    • Rest of Europe

Buy this Complete Report Now at https://www.coherentmarketinsights.com/insight/buy-now/5021

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:
Mr. Shah
Senior Client Partner - Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg

© 2022 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.